June 10, 2009

Effect of Telmisartan on Renal Outcomes: A Randomized Trial.

.   .   

This pre-specified subgroup analysis of the TRANSCEND study failed to show any significant benefit on renal outcomes between the intervention arm (using telmisartan) and placebo arm. This was not a study of chronic kidney disease patients, but rather examined patients with cardiovascular disease or diabetes, but without macroalbuminuria or heart failure.

Related Articles:

Chronic Kidney Disease, Hypertension, RAS Blockade

Comments are closed.